September 2011 in “Urology” This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.
46 citations
,
January 2005 in “PubMed” This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.
March 2009 in “The Journal of Urology” This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.
19 citations
,
June 2017 in “Asian journal of urology” This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.
9 citations
,
February 2022 in “Biomolecules” This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.